EGEA4 THE 30 YEAR FOLLOW UP OF THE EGEA STUDY

NCT06334705 | Recruiting

• 2 other identifiers: C22-112022-A02312- 41
• Study Type: interventional
• Target: 1,000
• Locations: 1 country
• Sites: 5

Brief Summary

Cardiovascular (CV) diseases affect 523 million people worldwide, and are the leading cause of death, accounting for over 18 million deaths (around 30% of all deaths) every year. CV diseases account for around 45% of all deaths in Europe, or around 140,000 deaths a year in France. Asthma is one of the main non-communicable diseases, with a significant societal and individual burden, particularly in subjects suffering from severe asthma. The prevalence of asthma worldwide has risen rapidly over the past five decades, and now affects 272 million people worldwide, representing a prevalence of around 3.6%. Asthma is often associated with multimorbidity. Allergic rhinitis, chronic sinusitis, sleep apnea syndrome, gastro-oesophageal reflux disease, obesity and hormonal disorders are among the most common conditions associated with asthma. More recently, other chronic conditions linked to asthma have been suggested, including CV diseases. Although data from the literature in recent years suggest that asthma is associated with an increased risk of major CV events, the underlying mechanisms remain poorly understood. In particular, it is not known whether asthma and CV disease share common etiological processes, such as anthropometric parameters, lifestyle, social, environmental and/or genetic factors, or whether CV disease is a direct consequence of certain features of asthma, such as systemic inflammation or asthma treatments. Our study is based on the hypothesis that the risk of CV events is increased in patients with asthma, which is supported by a growing body of scientific data.However, it remains to be determined to what extent this increased risk is a consequence of asthma or is linked to shared risk factors between asthma and CV health. We hypothesize that asthma, and more specifically adult and moderate-to-severe asthma, are associated with early markers of CV risk. Furthermore, by providing a better understanding of the mechanisms involved in this association, we hypothesize that EGEA\_30years may help to disentangle and prioritize actionable levers of life-threatening cardiovascular comorbidities in asthma.

Conditions

Healthy Volunteer EGEA4 Cohort

Keywords

Respiratory and cardiac health; Cohort; Epidemiology

Outcome Measures

Primary Outcomes (1)

• Framingham score variability between asthmatics and non-asthmatics

  The primary endpoint will be the variability of the Framingham score between asthmatics and non-asthmatics to assess the association between asthma and cardiovascular (CV) risk.

  during clinical examination

Secondary Outcomes (4)

• Aortic pulse wave velocity

  during clinical examination

• validated predictive biomarkers of CV disease (NTproBNP, Troponin(I) hs),

  during clinical examination

• Soluble ST2

  during clinical examination

• coronary calcium score

  during clinical examination

Study Arms (1)

participants can take part in any examinations they wish

OTHER

Other: blood test, food collection, hair collection, calcium scan, etc.

Interventions

blood test, food collection, hair collection, calcium scan, etc. OTHER

everything is specified during the phone call and in the consent form to be signed

participants can take part in any examinations they wish

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Have participated in at least one of the previous EGEA surveys;
• to be affiliated to a social security scheme or to be a beneficiary of such a scheme.

You may not qualify if:

• Person deprived of liberty by judicial or administrative decision;
• Person subject to a legal protection measure (safeguard of justice, curatorship or guardianship).

Sponsors & Collaborators

• Institut National de la Santé Et de la Recherche Médicale, France: lead
• APHP: collaborator
• Hospices Civils de Lyon: collaborator
• APHM: collaborator
• University Hospital, Grenoble: collaborator
• University Hospital, Montpellier: collaborator

Study Sites (5)

Centre Hospitalier Universitaire Grenoble Alpes

Grenoble, 38043, France

RECRUITING

Hopital de la Croix Rousse

Lyon, 69317, France

RECRUITING

APHM

Marseille, 13000, France

RECRUITING

Hôpital Arnaud De Villeneuve

Montpellier, 34295, France

RECRUITING

APHP - Hôpital Bichat Claude Bernard

Paris, 75018, France

RECRUITING

Related Links

• Related Info

MeSH Terms

Interventions

Hematologic Tests

Intervention Hierarchy (Ancestors)

Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques

Study Officials

• Valérie Siroux, PHD

  Institut National de la Santé Et de la Recherche Médicale, France

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Valérie Siroux, PHD

CONTACT

0476549451; valerie.siroux@univ-grenoble-alpes.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 18, 2024
• First Posted: March 28, 2024
• Study Start: February 15, 2024
• Primary Completion (Estimated): February 15, 2027
• Study Completion (Estimated): February 15, 2028
• Last Updated: September 19, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

FR (5)